Sign In
Buy IMUX
$14.17
-0.470 (-3.21%)
At Close: Jun 03, 2026
Immunic, Inc. to Participate in Investor Conference in December
06:30am, Tuesday, 26'th Nov 2024
NEW YORK, Nov. 26, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammator
Immunic's IMU-856 shows potential in gastrointestinal health trials - ICYMI
12:59pm, Saturday, 16'th Nov 2024
Immunic Inc (NASDAQ:IMUX) Chief Medical Officer Dr. Andreas Muehler talked with Proactive about the publication of the company's Phase 1 and Phase 1b clinical trial results for IMU-856 in The Lancet
Immunic reports positive Phase 1 results for celiac disease therapy published in The Lancet
09:39am, Wednesday, 13'th Nov 2024
Immunic Inc (NASDAQ:IMUX) announced that data from its phase 1/1b clinical trial for IMU-856, a small molecule targeting SIRT6, has been published in The Lancet Gastroenterology & Hepatology. The stud
– Includes Phase 1 Data in Healthy Human Subjects and Phase 1b Data in Celiac Disease Patients – NEW YORK , Nov. 13, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology compa
Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript
08:37am, Saturday, 09'th Nov 2024
Immunic, Inc. (NASDAQ:IMUX ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Jessica Breu - Vice President Investor Relations and Communications Daniel Vitt - Chief E
Immunic highlights progress in multiple sclerosis programs, targets 2025 milestones
08:58am, Thursday, 07'th Nov 2024
Immunic Inc (NASDAQ:IMUX) ended the third quarter with over $59 million in cash to advance its key clinical programs, including its lead candidate, vidofludimus calcium (IMU-838), for multiple scleros
Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
06:30am, Thursday, 07'th Nov 2024
– Positive Interim Analysis of Phase 3 ENSURE Program, Unblinded Independent Data Monitoring Committee Confirmed that Predetermined Futility Criteria Have Not Been Met and Recommended Trials Should
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
06:30am, Thursday, 31'st Oct 2024
– Webcast to be Held at 8:00 am ET on November 7, 2024 – NEW YORK , Oct. 31, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally
Immunic to Participate in Industry, Scientific and Investor Conferences in November
06:30am, Tuesday, 29'th Oct 2024
NEW YORK , Oct. 29, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammat
Immunic Phase 3 MS study advances following positive recommendation from independent committee
09:16am, Tuesday, 22'nd Oct 2024
Immunic Inc (NASDAQ:IMUX) announced a positive outcome from the interim futility analysis of its Phase 3 ENSURE program which is investigating its lead asset vidofludimus calcium in relapsing multiple
– Based on a Review of Unblinded Data, an Independent Data Monitoring Committee (IDMC) Confirmed that Predetermined Futility Criteria Have Not Been Met – – IDMC Also Recommended Continuing Trial
Immunic highlights lead asset's promise in multiple sclerosis at ECTRIMS Congress
08:43am, Wednesday, 18'th Sep 2024
Immunic Inc (NASDAQ:IMUX) announced that it is presenting key data for its lead asset vidofludimus calcium at the 40th Congress of the European Committee for Treatment and Research in Multiple Scleros
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
06:30am, Wednesday, 18'th Sep 2024
– Vidofludimus Calcium Consistently Reduce d Neurofilament Light Chain Levels, Compared to Placebo, in the Interim Analysis of the Phase 2 CALLIPER Trial, Across Age and Disability Levels at Baseli
Immunic drug targeting post-COVID syndrome in Phase 2 trial - ICYMI
08:30am, Saturday, 07'th Sep 2024
Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler joined Proactive to discuss a research update for the company's lead compound vidofludimus calcium. Vidofludimus calcium is being su
Immunic reports first patient enrolled in investigator-sponsored post-COVID syndrome trial
08:44am, Wednesday, 04'th Sep 2024
Immunic Inc (NASDAQ:IMUX) announced that the first patient has been enrolled in an investigator-sponsored Phase 2 trial of its lead asset vidofludimus calcium for post-COVID syndrome. The RAPID_REVIVE
